304853-89-2

Basic information

• Product Name: 2-(2-AMINO-5-BROMOPHENYL)PROPAN-2-OL
• Synonyms: 2-(2-AMINO-5-BROMOPHENYL)PROPAN-2-OL
• CAS NO: 304853-89-2
• Molecular Formula: C₉H₁₂BrNO
• Molecular Weight: 230.1
• Mol File: 304853-89-2.mol

Chemical Properties

• Boiling Point: 311.2±27.0 °C(Predicted)
• Appearance: /
• Density: 1.478±0.06 g/cm3(Predicted)
• PKA: 14.27±0.29(Predicted)
• CAS DataBase Reference: 2-(2-AMINO-5-BROMOPHENYL)PROPAN-2-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-AMINO-5-BROMOPHENYL)PROPAN-2-OL(304853-89-2)
• EPA Substance Registry System: 2-(2-AMINO-5-BROMOPHENYL)PROPAN-2-OL(304853-89-2)

Safety Data

• Hazardous Substances Data: 304853-89-2(Hazardous Substances Data)

Usage

Synonyms

2-amino-5-bromobenzyl alcohol

Physical Appearance

White to light yellow solid

Functional Groups

Hydroxyl (OH), amine (NH2), and bromine (Br) atom

Classification

Alcohol

Uses

Synthesis of pharmaceuticals and other organic compounds; versatile building block in organic synthesis for the production of various pharmaceutical and biologically active compounds

Safety

Handle with care, as it can be hazardous if not used properly.

Upstream product

• 29124-56-9 1-(2-amino-5-bromophenyl)ethanone 
• 75-16-1 methylmagnesium bromide 
• 52727-57-8 5-bromo-2-aminobenzoic acid methyl ester 
• 104670-74-8 methyl 2-amino-3-bromobenzoate 
• 5794-88-7 5-Bromo-2-aminobenzoic acid 
• 917-54-4 methyllithium 
• 63243-76-5 2-amino-5-bromobenzoic acid,ethyl ester 

Downstream Products

• 304858-44-4 6-bromo-2,4,4-trimethyl-1,4-dihydro-2H-1,3-benzoxazine 
• 21440-97-1 brofoxine 
• 304853-90-5 (1,4-dihydro-4,4-dimethyl-2-oxo-2H-3,1-benzoxazin-6-yl)boronic acid 
• 304853-28-9 6-(3-chlorophenyl)-4,4-dimethyl-1,4-dihydro-2H-benzo[d][1,3]oxazine-2-one 
• 304854-37-3 6-(2-chloro-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
• 305799-74-0 6-(4-Chloro-phenyl)-4,4-dimethyl-1,4-dihydro-benzo [d] [1,3]-oxazin-2-one 
• 304854-36-2 6-(3-Methoxy-phenyl)4,4-dimethyl-1,4-dihydro-benzo [d] [1,3]-oxazin-2one 
• 304854-26-0 6-(3-Fluoro-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d] [1,3]-oxazin-2-one 
• 304853-36-9 3-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-benzo[d][1,3]oxazin-3-yl)benzonitrile 
• 304854-09-9 6-(3-Chloro-5-fluoro-phenyl)4,4-dimethyl-1,4-dihydro-benzo[d] [1,3]oxazin-2-one 
• 304854-45-3 6-(3-Chloro-4-fluoro-phenyl)-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
• 304853-30-3 PRA-910 
• 304854-07-7 5-(4,4-Dimethyl-2-oxo-1,4-dihydro-2H-benzo [d] [1,3]oxazin-6-yl)-2-fluoro-benzonitrile 
• 304853-34-7 6-Bromo-4,4-dimethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-thione 

Relevant articles and documents

Alkynyl Benzoxazines and Dihydroquinazolines as Cysteine Targeting Covalent Warheads and Their Application in Identification of Selective Irreversible Kinase Inhibitors

With a resurgence in interest in covalent drugs, there is a need to identify new moieties capable of cysteine bond formation that are differentiated from commonly employed systems such as acrylamide. Herein, we report on the discovery of new alkynyl benzoxazine and dihydroquinazoline moieties capable of covalent reaction with cysteine. Their utility as alternative electrophilic warheads for chemical biological probes and drug molecules is demonstrated through site-selective protein modification and incorporation into kinase drug scaffolds. A potent covalent inhibitor of JAK3 kinase was identified with superior selectivity across the kinome and improvements in in vitro pharmacokinetic profile relative to the related acrylamide-based inhibitor. In addition, the use of a novel heterocycle as a cysteine reactive warhead is employed to target Cys788 in c-KIT, where acrylamide has previously failed to form covalent interactions. These new reactive and selective heterocyclic warheads supplement the current repertoire for cysteine covalent modification while avoiding some of the limitations generally associated with established moieties.

Heterocyclic com pounds and organic light-emitting diode including the same

The present invention relates to a novel heterocyclic compound and an organic light emitting element including the same as a light-emitting material and, more specifically, to a heterocyclic compound having excellent light emission properties, such as a driving voltage, luminous efficiency, and lifetime, and an organic light emitting element including the same. Since the heterocyclic compound according to the present invention is more stable compared to conventional materials and has the excellent light emission properties for a driving voltage or current efficiency, the organic light emitting element including the same can be driven with a low-voltage and light emission efficiency can be improved.

SUBSTITUTED BENZO[d][1,3]OXAZIN-2(4H)-ONES AND RELATED DERIVATIVES AND THEIR USES FOR MODULATING THE PROGESTERONE RECEPTOR

Compounds of formula (I), or pharmaceutically acceptable salts thereof, are provided, wherein R1-R6 and X are defined herein. Also provided are methods of preparing the compounds of formula (I), pharmaceutical compositions and kits containing a compound of formula (I), as are methods of treating endometriosis, hormone-dependent carcinomas, leiomyoma, fibroids, dysfunctional bleeding, polycystic ovary syndrome, and menopause related symptoms; methods of contraception; methods of providing hormone replacement therapy; methods of stimulating food intake; methods of synchronizing estrus; and methods of treating symptoms of premenstrual syndrome and premenstrual dysphoric disorder by administering to a mammal in need thereof a pharmaceutically effective amount of a compound of formula (I).

7-Aryl 1,5-dihydro-benzo[e][1,4]oxazepin-2-ones and analogs as non-steroidal progesterone receptor antagonists

Novel 7-aryl benzo[1,4]oxazepin-2-ones were synthesized and evaluated as non-steroidal progesterone receptor (PR) modulators. The structure activity relationship of 7-aryl benzo[1,4]oxazepinones was examined using the T47D cell alkaline phosphatase assay. A number of 7-aryl benzo[1,4]oxazepinones such as 10j and 10v demonstrated good in vitro potency (IC50 of 10-30 nM) and selectivity (over 100-fold) at PR over other steroidal receptors such as glucocorticoid and androgen receptors (GR and AR). Several 7-aryl benzo[1,4]oxazepinones were active in the rat uterine decidualization model. In this in vivo model, compounds 10j and 10u were active at 3 mg/kg when dosed orally.

1,5-Dihydro-benzo[e][1,4]oxazepin-2(1H)-ones containing a 7-(5′-cyanopyrrol-2-yl) group as nonsteroidal progesterone receptor modulators

A series of novel 7-(5′-cyanopyrrol-2-yl) substituted benzo[1,4]oxazepin-2-ones were prepared and tested for their progesterone receptor (PR) agonist or antagonist activity in the alkaline phosphatase assay using the human T47D breast carcinoma cell line.

AROMATIC SULFONE COMPOUND AS ALDOSTERONE RECEPTOR MODULATOR

The present invention provides a compound represented by the following formula (I): [wherein, A represents a group of the following formula (A-1): etc., R1 and R2 each independently represent a hydrogen atom etc., Z represents CR3 etc., W represents CR4 etc., Q represents CR5 etc., R3, R4 and R5 each independently represent a hydrogen atom etc., Y represents an oxygen atom or sulfur atom, X represents an oxygen atom etc. and B represents an optionally substituted aryl group or optionally substituted heteroaryl group], the prodrug thereof or the pharmaceutically acceptable salt thereof for preventing or treating various diseases such as hypertesion, cerebral stroke, cardiac failure, etc.

7-aryl 1,5-dihydro-4, 1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators

This invention provides progesterone receptor modulators having the structure: wherein R1 to R7, X, and Q are as defined in the specification; or a pharmaceutically acceptable salt thereof.

Synthesis and structure-activity relationship of novel 6-aryl-1,4- dihydrobenzo[d][1,3]oxazine-2-thiones as progesterone receptor modulators leading to the potent and selective nonsteroidal progesterone receptor agonist tanaproget

Tanaproget represents a potential first-in-class nonsteroidal PR agonist for contraception with improved safety and side effect profiles versus currently available steroidal oral contraceptives. Additional SAR, biological activity, and structural information from a tanaproget/hPR-LBD (hPR-LBD = human progesterone receptor ligand binding domain) cocrystal structure will also be presented.

Quinazolinone and benzoxazine derivatives as progesterone receptor modulators

This invention provides compounds which are agonists and antagonists of the progesterone receptor having the general structure: wherein: R1and R2are independently selected from H, CORA, or NRBCORA, or optionally substituted alkyl, alkenyl, alknyl, cycloalklyl, aryl, or heterocyclic moieties; or R1and R2are fused to form: 3 to 8 membered spirocyclic alkyl, alkenyl or heterocyclic rings; RAis H or optionally substituted alkyl, aryl, alkoxy, or aminoalkyl groups; RBis H, C1to C3alkyl, or substituted C1to C3alkyl; R3is H, OH, NH2, CORCor optionally substituted alkyl, alkenyl, or alkynyl; RCis H or optionally substituted alkyl, aryl, alkoxy, or aminoalkyl; R4is H, halogen, CN, NO2, or optionally substituted alkyl, alkynyl, alkoxy, amino or aminoalkyl; R5is an optionally substituted benzene or five or six membered ring with 1, 2, or 3 heteroatoms selected from O, S, SO, SO2or NR6; R6is H or C1to C3alkyl; G1is O, NR7, or CR7R8; G2is CO, CS, or CR7R8; provided that when G1is O, G2is CR7R8, and G1and G2cannot both be CR7R8; R7and R8are H or an optionally substituted alkyl, aryl, or heterocyclic moiety; or pharmaceutically acceptable salt thereof, and methods using these compounds in mammals as agonists or antagonists of the progesterone receptor.

Potent nonsteroidal progesterone receptor agonists: Synthesis and SAR study of 6-aryl benzoxazines

Novel 6-aryl benzoxazines were prepared and examined as progesterone receptor (PR) modulators. In contrast to the structurally related 6-aryl dihydroquinoline PR antagonists, the 6-aryl benzoxazines were potent PR agonists. Compounds 4e, 5b, and 6a with the 2,4,4-trimethyl-1,4-dihydro-2H-benzo[d][1,3]oxazine core were the most potent PR agonists in the series with sub-nanomolar activities (EC50 0.20-0.35 nM). Compound 6a was more potent than progesterone (P4) in the in vivo decidualization assay in an ovariectomized female rat model by subcutaneous administration with an ED50 of 1.5 mg/kg (vs 5.62 mg/kg for P4).